Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Inflammatory Demyelinating Polyneuropathy: full-pipeline trial registry
8 of 12 indexed Chronic Inflammatory Demyelinating Polyneuropathy trials are currently recruiting.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 8 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Chronic Inflammatory Demyelinating Polyneuropathy: 12 US clinical trials tracked, 8 recruiting.
Chronic Inflammatory Demyelinating Polyneuropathy is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is argenx, running 3 of these trials.
Enrollment posture brief
Registry condition chronic-inflammatory-demyelinating-polyneuropathy
OPEN 8 | RECR 67% | LATE 6 | EARLY 4 | RANK #1429 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Chronic Inflammatory Demyelinating Polyneuropathy lists 8 open slots (67% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Inflammatory Demyelinating Polyneuropathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Inflammatory Demyelinating Polyneuropathy is recruiting above its size-band peers.
8 of 12 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Chronic Inflammatory Demyelinating Polyneuropathy research.
argenx accounts for 3 of 12 trials (25%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Chronic Inflammatory Demyelinating Polyneuropathy enrolment sits around 160 participants.
Median target enrolment is 160 among the 12 trials that report a genuine target (sentinel values excluded). 5 of those (41.7%) plan for fewer than 100 participants.
-
Chronic Inflammatory Demyelinating Polyneuropathy research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
NCT06858579
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
argenx
NCT06920004
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences
NCT07032662
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Kedrion S.p.A.
NCT06752356
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
argenx
NCT07091630
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi
NCT06290141
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
Nuvig Therapeutics
NCT07027111
IVIG vs SCIG in CIDP
Rutgers, The State University of New Jersey
NCT05584631
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
Immunovant Sciences
NCT05581199
A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
argenx
NCT06637072
IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
University of Minnesota
NCT02414490
Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
University of South Florida
NCT02465359
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Inflammatory Demyelinating Polyneuropathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Inflammatory Demyelinating Polyneuropathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Inflammatory Demyelinating Polyneuropathy page
12 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Chronic Inflammatory Demyelinating Polyneuropathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- argenx sponsors the most Chronic Inflammatory Demyelinating Polyneuropathy trials on record, review their full trial history before evaluating a specific study. See argenx's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Inflammatory Demyelinating Polyneuropathy condition card totals 12 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.